GMP for Cannabis: Why GMP is Your Export Passport

In the European Union, any manufacturer of medicines (including cannabis-derived medicines) intended for the EU market must comply with EU GMP, no matter where the site is located.

EU GMP is often viewed as more stringent than many other jurisdictions, requiring rigorous documentation, process validation, equipment qualification and more.

Some producers outside the EU choose to produce under less stringent frameworks—or partner with EU-GMP certified processors rather than become certified themselves. For example, a Greek facility elected to focus on GACP cultivation and outsource final processing rather than pursue full EU-GMP certification.

In the U.S., cannabis remains federally illegal, and there is no definitive federal GMP requirement for most cannabis operations, but that’s rapidly changing, and many export-minded companies are treating GMP as table stakes.

Globally, markets like Australia, Canada, Colombia, Lesotho, and others are aligning with GMP or equivalent standards if they want to play in export markets.

Achieving full GMP certification can be a long, costly process (often 12-24 months or more) and may require facility upgrades, documentation systems, validation protocols, staff training, etc.

However, operational compliance with GMP principles, regardless of formal certification, locks in disciplined manufacturing processes, repeatable batch control, traceability, sanitation, validated equipment, staff training, all of which build operational resilience and quality readiness.

In many markets you’ll find that the ability to export, partner or secure investment hinges not only on the certificate, but on robust documented practices. In other words: you may not yet have a certificate, but if you have compliance in place you’re far ahead of peers.

Interstate Commerce/ Multi-State Supply: If you are in a multi-state operation or servicing markets beyond your home state, regulators, compliance officers and purchasers will eventually need GMP or equivalent quality assurances.

International Export: For example, to access EU medicinal cannabis markets, exporters must either hold or demonstrate equivalency to EU GMP. Without it, access is blocked or severely restricted.

Brand & Customer Trust: As consumers and regulators mature, “good enough” is no longer enough. GMP consistency signals premium quality and can support higher price realization.

Flexibility for Growth: Even if you aren’t exporting today, having compliant systems means you can pivot quickly when markets open or demand increases.

Risk Reduction: GMP standards mitigate contamination, recalls, process failures and inconsistent potency, each of which represents operational and insurance risk.

Market Access Edge: When a buyer or distributor sees “GMP-ready” or “GMP certified” your facility is immediately more attractive. You don’t have to start from scratch.

Operational Efficiency: The discipline required by GMP often reveals inefficiencies, strengthens SOPs, validates equipment, and elevates training—which all drive down costs and waste.

Gap Analysis & Risk Assessment: Map your current processes against GMP and export market requirements. Identify where you are and where you need to go.

Develop Quality Systems & Documentation: SOPs, batch records, equipment qualification, change control, hygiene, staff training—all are core to GMP.

Implement & Monitor Compliance Practices: Build the habit of documentation, audits, corrective/preventive action, and continuous improvement.

Decide Certification Timing & Strategy: Determine whether you will pursue full certification now, partner with a certified facility, or build compliance first and certify later.

Build the Export/Scaling Plan: Align your operations with the markets you are targeting (state rollout, interstate supply, export). Understand the regulatory trigger points (e.g., EU GMP for EU exports).

Leverage Your Compliance in Sales/Insurance/Investment Pitch: Use your documented quality systems as a differentiator when negotiating with insurers, investors, or buyers.